Loading organizations...
§ Private Profile · 1616 Eastlake Avenue E Suite 400 Seattle, WA 98102, USA
Biotechnology company developing conditionally active protein-based therapeutics for oncology, focused on immune modulators.
Bonum Therapeutics is a Seattle, Washington-based biotechnology company that develops conditionally active protein-based therapeutics using allosteric regulation to treat targeted oncology and immunology patients. The organization focuses on engineering immune modulators, such as cytokines, that switch from inactive to active states only upon binding to specific cellular targets, thereby reducing systemic toxicity and enhancing targeted anti-tumor efficacy. Operating with an initial 26-member team, the enterprise was spun out following the $250 million upfront acquisition of its predecessor, Good Therapeutics, by multinational healthcare company Roche in August 2022. Shortly after this corporate spinout, the firm secured $93 million in Series A funding backed by a syndicate of venture capital investors including Roche Venture Fund, Rivervest Venture Partners, Vivo Capital, and Digitalis Ventures. Bonum Therapeutics was officially founded in 2021 by serial biotechnology entrepreneur John Mulligan, PhD.
Bonum Therapeutics has raised $93.0M across 1 funding round.
Bonum Therapeutics has raised $93.0M in total across 1 funding round.
Bonum Therapeutics has raised $93.0M across 1 funding round. Most recently, it raised $93.0M Series A in November 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2022 | $93M Series A | — | Codon Capital, Digitalis Ventures, Rivervest, Roche Venture Fund, 3X5 Partners, RiverVest Venture Partners, Roche, Mitchell Mutz | Announced |
Bonum Therapeutics has raised $93.0M in total across 1 funding round.
Bonum Therapeutics's investors include Codon Capital, Digitalis Ventures, RiverVest, Roche Venture Fund, 3x5 Partners, RiverVest Venture Partners, Roche, Mitchell Mutz.
Bonum Therapeutics is a Seattle-based biotechnology company developing a proprietary technology platform for antibody-regulated biologics that enable precision activation of therapies, primarily targeting oncology with potential expansion into autoimmunity, metabolic disorders, and pain management.[1][2][3] The platform creates conditionally active molecules that "switch on" only in targeted disease environments, aiming to deliver highly active treatments with reduced toxicity and improved safety profiles; two programs are currently in preclinical development.[1][2][4]
This approach builds on validated technology from its predecessor, Good Therapeutics, which was acquired by Roche in 2022 for a PD-1-regulated IL-2 program, demonstrating early proof of concept for safer, more effective biologics in hard-to-treat areas.[1]
Bonum Therapeutics emerged from the technology and expertise of Good Therapeutics, a predecessor company acquired by Roche in 2022, carrying forward pioneering work on conditionally active therapeutic agents—biologics engineered to activate precisely in disease sites.[1][4] Headquartered in Seattle, Washington, the company focuses on antibody-based mechanisms for regulated, targeted medicines, with oncology as its initial priority area.[2]
While specific founders are not detailed in available sources, Bonum was established post-acquisition to independently advance this platform, leveraging the Roche-validated IL-2 program as a foundational milestone that provided early traction and de-risked the core technology.[1]
Bonum Therapeutics rides the wave of precision oncology and conditional biologics, a trend accelerating with advances in antibody engineering and targeted therapies amid rising demand for safer immunotherapies beyond PD-1/PD-L1 inhibitors.[1][4] Timing aligns with post-2022 biopharma shifts toward platforms enabling tissue-specific activation, fueled by market forces like high cancer prevalence, regulatory emphasis on reduced adverse events, and investor interest in de-risked assets from prior exits like Roche's acquisition.[1]
By influencing the ecosystem through preclinical advancements, Bonum contributes to next-gen biologics that could reshape treatment paradigms, potentially partnering with or attracting big pharma seeking bolt-on innovations in immunology and beyond.[2][3]
Bonum is poised to advance its two preclinical programs toward IND filings, potentially expanding the platform to additional indications as data emerges, with key catalysts including proof-of-concept studies and partnerships mirroring its predecessor's Roche deal.[1][2] Trends like AI-aided drug design and combo immunotherapy will shape its path, amplifying platform scalability amid a biotech funding rebound favoring validated tech.[4]
As a post-acquisition spinout, Bonum's influence could evolve through milestone-driven growth, positioning it as a leader in safer targeted biologics and delivering on the promise of precision activation that began with its foundational Roche-validated assets.[1]